Lipocine Statistics
Share Statistics
Lipocine has 5.35M shares outstanding. The number of shares has increased by 0.6% in one year.
| Shares Outstanding | 5.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.19M |
| Failed to Deliver (FTD) Shares | 50 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 107.54K, so 2.01% of the outstanding shares have been sold short.
| Short Interest | 107.54K |
| Short % of Shares Out | 2.01% |
| Short % of Float | 2.07% |
| Short Ratio (days to cover) | 2.8 |
Valuation Ratios
The PE ratio is -0.9 and the forward PE ratio is -4.11.
| PE Ratio | -0.9 |
| Forward PE | -4.11 |
| PS Ratio | -5.16 |
| Forward PS | 9.5 |
| PB Ratio | 0.72 |
| P/FCF Ratio | -1.24 |
| PEG Ratio | n/a |
Enterprise Valuation
Lipocine Inc. has an Enterprise Value (EV) of 14.72M.
| EV / Earnings | -0.9 |
| EV / Sales | -5.16 |
| EV / EBITDA | -0.9 |
| EV / EBIT | -0.82 |
| EV / FCF | -1.24 |
Financial Position
The company has a current ratio of 8.69, with a Debt / Equity ratio of 0.
| Current Ratio | 8.69 |
| Quick Ratio | 8.69 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.08 |
| Cash Flow / Debt | -691.25 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.8% and return on capital (ROIC) is -87.96%.
| Return on Equity (ROE) | -0.8% |
| Return on Assets (ROA) | -0.71% |
| Return on Capital (ROIC) | -87.96% |
| Revenue Per Employee | -167.70K |
| Profits Per Employee | -961.89K |
| Employee Count | 17 |
| Asset Turnover | -0.12 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 755 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 13.14% in the last 52 weeks. The beta is 1.19, so Lipocine 's price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | 13.14% |
| 50-Day Moving Average | 5.02 |
| 200-Day Moving Average | 5.43 |
| Relative Strength Index (RSI) | 42.83 |
| Average Volume (20 Days) | 30.12K |
Income Statement
In the last 12 months, Lipocine had revenue of -2.85M and earned -16.35M in profits. Earnings per share was -3.14.
| Revenue | -2.85M |
| Gross Profit | -2.85M |
| Operating Income | -17.93M |
| Net Income | -16.35M |
| EBITDA | -16.32M |
| EBIT | -17.93M |
| Earnings Per Share (EPS) | -3.14 |
Balance Sheet
The company has 4.77M in cash and 17.17K in debt, giving a net cash position of 4.75M.
| Cash & Cash Equivalents | 4.77M |
| Total Debt | 17.17K |
| Net Cash | 4.75M |
| Retained Earnings | -199.78M |
| Total Assets | 20.70M |
| Working Capital | 18.92M |
Cash Flow
In the last 12 months, operating cash flow was -11.87M and capital expenditures -13.17K, giving a free cash flow of -11.88M.
| Operating Cash Flow | -11.87M |
| Capital Expenditures | -13.17K |
| Free Cash Flow | -11.88M |
| FCF Per Share | -2.25 |
Margins
Gross margin is 100%, with operating and profit margins of 628.98% and 573.59%.
| Gross Margin | 100% |
| Operating Margin | 628.98% |
| Pretax Margin | 573.57% |
| Profit Margin | 573.59% |
| EBITDA Margin | 572.56% |
| EBIT Margin | 628.98% |
| FCF Margin | 416.69% |
Dividends & Yields
LPCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -67.53% |
| FCF Yield | -47.81% |
Analyst Forecast
The average price target for LPCN is $10, which is 115.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 115.1% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 12, 2023. It was a backward split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | backward |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | -2.68 |
| Piotroski F-Score | 2 |